Children's Hospital of Eastern Ontario
Ottawa, Ontario, K1H 8L1, Canada
NCT Number: NCT06816875
The goal of this clinical trial is to compare the caregiver's user experience, and overall impacts on an infant's cold symptoms between four nasal aspirator devices. These devices are normally used to relieve congestion in infants. when they are sick by softening and suctioning mucus from the nose.
The main questions it aims to answer are:
What is the caregiver's user experience of the NozeBot electric nasal aspirator compared to three commonly accessible nasal aspirator devices?
Are there changes in the infant's sleeping, feeding, or breathing as reported by the caregiver when using the NozeBot compared to the three other nasal aspirator devices?
Are there changes in their caregiver's habits when using the NozeBot compared to the three other nasal aspirator devices?
Researchers will compare the self-reported measures of caregiver's user experience, reported changes to their infant's symptoms, and reported changes to their own sleeping and care habits between the NozeBot electric nasal aspirator and three comparator devices: the NoseFrida SnotSucker, the hydraSense Baby Nasal Aspirator Kit, and the Braun electric nasal aspirator.
Participants will be assigned to receive one of the four devices at the start of their participation. They will be asked to use the assigned device at home according to the device instructions during two periods: (1) for 10 days while their infant is sick, and (2) for up to 3 months after.
During these periods, participants will be asked to complete online surveys at predetermined intervals to report the user experience, any changes to their infant's sleeping, feeding or breathing, and any changes to their own sleeping habits and perceived stress levels. These intervals for survey completion are: (i) after 1-2 days of use while their infant is sick, (ii) after 4-5 days of use while their infant is sick, (iii) after 7-10 days of use while their infant is sick, and then (iv) biweekly for 3 months.
Looking for future studies?
Notify MeAll sexes
Interventional
Not applicable
Ottawa, Ontario, K1H 8L1, Canada
Healthy volunteers accepted: Yes
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
A parent(s)/caregiver(s)/family will be eligible to participate if:
Exclusion criteria
A parent(s)/caregiver(s)/family will be ineligible to participate if:
The NozeBot is a rechargeable, battery-operated baby nasal aspirator with a nosepiece that loops directly onto the caregivers fingers for ease of use, and is intended to be held so it sits just inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
The NoseFrida is nose-to-mouth nasal suctioning device with a disposable hygienic filter. The nosepiece is a larger tube that is to be held so it sits against and not inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
The hydraSense Baby Nasal Aspirator Starter Kit is a nose-to-mouth nasal suctioning device with a disposable hygienic filter. The kit contains pre-proportioned saline solution vials to liquify mucus prior to suctioning. The nosepiece is intended to be held so it sits inside the nose to create a seal. It will be used according to its manufacturer's instructions for use in this study.
The Braun nasal aspirator is a battery-operated nasal suctioning device with a washable collection chamber for mucus. There are two nosepiece sizes to accommodate a best fit in the nose. It will be used according to its manufacturer's instructions for use in this study.
Time frame: This is reported at all follow ups, from the first survey completed at 1-2 days of device use to the final survey completed at the end of the third month of use per participant
The first measure of user experience is the self-reported rating by the caregivers on the ease of use of the device, including device set up, use, and cleaning after use. This is reported on a 5-point Likert scale (1 - difficult to 5 - easy) at each of the survey follow ups.
Time frame: This is reported at the 7-10 days of device use to the final survey completed at the end of the third month of use per participant.
The second measure of user experience is the caregiver-reported satisfaction with the device, including confidence that the device is helping their infant, and that the device's power is sufficiently removing mucus. This is reported on a 5-point Likert scale (1 - very dissatisfied to 5 - very satisfied) once at the 7-10 days of use while their child is sick, and at each bi-weekly survey over the 3 months.
Time frame: This is reported at the 7-10 days of device use to the final survey completed at the end of the third month of use per participant.
The third measure of user experience is the a rating by the caregiver on whether they would recommend the device to someone when their child is sick (also known as Net Promoter Score). This is reported on a 5-point Likert scale (1 - very unlikely to 5 - very likely) once at the 7-10 days of use while their chlid is sick, and at each bi-weekly survey over the 3 months.
Time frame: This is reported at the 1-2 days of use, 4-5 days of use, and 7-10 days of use follow up surveys.
Recorded as self-reported perceived changes to the caregivers' sleeping habits during the time that their child is sick since they started using the device in the study. This is reported on a 5-point Likert scale (1 - much less than normal to 5 - a lot more than normal) at the 1-2 days of use, 4-5 days of use, and 7-10 days of use follow up surveys.
Time frame: This is reported at all follow ups, from the first survey completed at 1-2 days of device use to the final survey completed at the end of the third month of use per participant
Recorded as self-reported perceived changes to the caregivers' ability to take care of their child during the time that their child is sick since they started using the device in the study. This is reported on a 5-point Likert scale (1- much less able to 5 - a lot more capable) at each of the survey follow ups.
Time frame: This is reported at all follow ups, from the first survey completed at 1-2 days of device use to the final survey completed at the end of the third month of use per participant
Recorded as self-reported perceived changes to the caregivers' stress levels experienced while their child is sick since they started using the device in the study. This is reported on a 5-point Likert scale (1- strongly disagree to 5 - strongly agree) at each of the survey follow ups.
Time frame: This is reported at the 1-2 days of use, 4-5 days of use, and 7-10 days of use follow up surveys.
Reported as caregiver-rated perceived changes in their infant's sleeping habits since they started using the device in the study on a 7-point Likert scale (1 - sleeping much worse to 4 - no changes in sleep to 7 - sleeping much better).
Time frame: This is reported at the 1-2 days of use, 4-5 days of use, and 7-10 days of use follow up surveys.
Reported as caregiver-rated perceived changes in their infant's feeding habits since they started using the device in the study on a 7-point Likert scale (1 - much harder to feed to 4 - no changes to feeding to 7 - much easier to feed).
Time frame: This is reported at all follow ups, from the first survey completed at 1-2 days of device use to the final survey completed at the end of the third month of use per participant
Reported as caregiver-rated perceived changes in their infant's breathing since they started using the device in the study on a 4-point Likert scale (1 - no change in breathing to 4 - breathing a lot better).
Children's Hospital of Eastern Ontario
Other
Comparative Analysis of Commercially Available Nasal Aspirators in Infants
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02484417
Infections, Respiratory Tract Diseases
Bethesda, Maryland, United States
View Trial DetailsNCT06065176
COVID-19, Coronaviridae Infections
Salt Lake City, Utah, United States
View Trial DetailsNCT06573814
Infections, Respiratory Tract Diseases
London, Ontario, Canada
View Trial DetailsNCT06689995
Infections, Respiratory Tract Diseases
Ahmedabad, Gujarat, India
View Trial Details